Contract analysis

I. EXECUTIVE SUMMARY Dr. Lawrence Keating's expert report on damages was served on June 15, 2025, in compliance with the Court's scheduling order. The report presents three distinct but complementary damages theories, each grounded in well-established Federal Circuit precedent and supported by extensive financial and economic analysis. The three theories are summarized as follows: First, Dr. Keating calculates lost p

II. BACKGROUND ON DR. KEATING AND RETENTION A. Qualifications and Engagement Dr. Lawrence Keating is a Managing Director at Meridian Economic Consulting Group, LLC, a nationally recognized economic consulting firm headquartered at 233 South Wacker Drive, Suite 4400, Chicago, Illinois 60606. Dr. Keating was retained by Calderwood & Harkness LLP on behalf of Optiwave Semiconductor Corp. pursuant to a retention agreemen

III. OVERVIEW OF DR. KEATING'S DAMAGES OPINIONS This section provides a detailed summary of each of Dr. Keating's three damages theories, as set forth in his expert report. The purpose is to ensure that the preparation team and Dr. Keating himself have a common and precise understanding of the analytical framework, key assumptions, and numerical conclusions that will be the subject of cross-examination. A. Theory 1:

1. OWS–Terralink Semiconductor License (2020): Running royalty rate of 6.5% on licensed revenue of approximately $45 million. This license covered a subset of the patents at issue in this case and involved a smaller portfolio. Dr. Keating treats this as a floor because the license involved fewer patents and a licensee with a smaller competitive overlap with OWS.

2. OWS–NovaWave Corp. License (2021): Running royalty rate of 9.0% on licensed revenue of approximately $22 million. This is the most directly comparable license: it involved three of the four asserted patents in this case and was negotiated under circumstances analogous to the hypothetical negotiation at issue. The higher rate reflects the stronger patent position and the closer competitive relationship.

3. OWS–Helix Integrated Photonics License (2022): Running royalty rate of 7.75% plus a $2.5 million upfront payment, on licensed revenue of approximately $68 million. This license involved similar silicon-photonics transceiver technology. The upfront payment component reflects the licensee's desire for certainty and reduced per-unit royalty exposure. Dr. Keating calculates the effective all-in rate at approximately 8

4. Stratos Photonics v. ArcLight Systems Settlement (2019): Running royalty rate of 8.0%, reached as part of a post-litigation settlement in a silicon-photonics patent dispute. Dr. Keating treats this as an industry comparable that validates market rates for licenses involving similar technology.

5. Coreline Technologies v. Prisma Semiconductor Cross-License (2021): Effective royalty rate of 10.2%, derived from a cross-license agreement with a balancing payment. The higher effective rate reflects the strength of the licensor's patent position and the value attributed to the licensed technology. Dr. Keating adjusts this rate downward in his analysis to account for differences in the scope and context of the cr

IV. ANTICIPATED AREAS OF CROSS-EXAMINATION This section identifies the primary areas where HVC is expected to focus its cross-examination of Dr. Keating, explains the nature of the anticipated challenges, and provides specific preparation points for Dr. Keating's responses. For each area, we also identify key documents that Dr. Keating should review in preparation. A. Market-Share Displacement (38.2%)

1. Expected Challenge HVC will almost certainly attack the 38.2% market-share displacement figure as the linchpin of Dr. Keating's lost-profits analysis. This figure drives the entire lost-profits calculation: if HVC can reduce or eliminate it, the lost-profits theory falls and the entire damages analysis shifts to the lower reasonable-royalty framework. We anticipate the following specific lines of attack: Derivatio

2. Preparation Points for Dr. Keating Dr. Keating should be thoroughly prepared to defend the 38.2% figure by emphasizing the rigor of his bottom-up methodology and the factual foundation for his conclusions: Methodology. Dr. Keating should emphasize that the 38.2% figure was derived through a bottom-up, customer-by-customer analysis of actual purchasing patterns, vendor-approval status, and competitive dynamics at e

3. Documents to Review • Market Share Displacement Analysis (internal, June 2024) • Dr. Michaud deposition transcript (November 19, 2024) — specifically passages where she could not identify non-infringing alternatives • Falk industry report, particularly sections addressing the competitive landscape, customer purchasing patterns, and vendor-approval dynamics among hyperscale data-center operators • Lumicore customer

1. Expected Challenge Apportionment is one of the most actively litigated issues in patent damages law, and HVC will devote significant attention to challenging Dr. Keating's use of the entire accused-product revenue as the royalty base. The Federal Circuit has repeatedly emphasized that patent damages must be apportioned to reflect the value attributable to the patented features, as distinct from the value of unpate

2. Preparation Points for Dr. Keating Dr. Keating should be prepared to address the apportionment challenge on multiple levels: The Transceiver Module Is the SSPPU. Dr. Keating's primary position is that the accused transceiver modules (LumiLink 400G-ZR+, LumiLink 800G-DR8, LumiEdge 1600G-LR) are themselves the smallest salable patent-practicing units. The patented waveguide multiplexer, thermal management micro-chan

3. Documents to Review • Apportionment Analysis Memorandum (internal, August 2024) • Lumicore marketing materials for accused products (from Lumicore's document production), particularly materials highlighting performance attributes enabled by patented technologies • Falk industry report sections on technology value drivers and the commercial significance of the patented innovations • Benchmark Semiconductor Analysis

1. Expected Challenge HVC will mount a sustained challenge to Dr. Keating's proposed 8.5% royalty rate. The reasonableness of the royalty rate is often the single most consequential variable in a Georgia-Pacific analysis, and even a small reduction in the rate (e.g., from 8.5% to 4.0%) would roughly halve the reasonable-royalty component of damages. We anticipate the following lines of attack: Comparability of the Li

2. Preparation Points for Dr. Keating Dr. Keating should be prepared to walk through each comparable license in detail, explain its relevance, and address the adjustments he made to account for differences between each comparable and the hypothetical negotiation in this case: OWS–Terralink Semiconductor (2020, 6.5%). This license involved a subset of the patents at issue in the present case and covered a licensee wit

3. Documents to Review • Comparable License Analysis (internal, July 2024) • Dr. Keating Damages Report — Appendix B: Georgia-Pacific Factor Analysis • Dr. Keating Damages Report — Appendix C: Royalty Rate Benchmarking • Hypothetical Negotiation Scenario (internal, May 2024) • Actual license agreements for all five comparables (as produced in discovery or obtained through public sources) • Lumicore financial data reg

1. Expected Challenge HVC will challenge the construct and assumptions of Dr. Keating's hypothetical negotiation analysis, seeking to undermine the foundation for his reasonable royalty opinion. Several specific lines of attack are anticipated: Negotiation Date. HVC may challenge the selection of Q2 2022 as the hypothetical negotiation date. In particular, HVC may argue that one of the four asserted patents — the '01

2. Preparation Points for Dr. Keating Q2 2022 Is the Correct Date. Dr. Keating should be firm that Q2 2022 is the appropriate hypothetical negotiation date under Federal Circuit precedent. The hypothetical negotiation is deemed to take place immediately before the first infringing sale. See Georgia-Pacific, 318 F. Supp. at 1120; Lucent, 580 F.3d at 1324. The first accused product, the LumiLink 400G-ZR+, was launched

1. Expected Challenge HVC will probe the reliability and verification of the financial data underlying Dr. Keating's analysis. This line of questioning serves a dual purpose: it may support a Daubert challenge (arguing that Keating's opinions lack a reliable factual foundation) and it may undermine the credibility of specific numerical inputs to the damages calculation. Revenue Projections. HVC will challenge the pro

2. Preparation Points for Dr. Keating Revenue Sources. Dr. Keating should be prepared to identify the specific sources for all revenue figures used in his analysis. For Lumicore's accused-product revenues, the figures are sourced from: • Lumicore's Form 10-K annual reports and quarterly filings with the SEC, which report segment-level revenue; • Lumicore's detailed product-line financial data produced in discovery pu

1. Expected Challenge HVC will vigorously contest any enhancement of damages for willful infringement. The enhancement component, while constituting approximately $43.6 million of the $210 million demand, is particularly contentious because it rests on a finding of willfulness — a determination that HVC will strenuously resist. Specific expected challenges include: Read Factors. HVC will argue that the Read factors d

2. Preparation Points for Dr. Keating Scope of Keating's Role. Dr. Keating must be clear about the limited scope of his role regarding willful infringement. His report calculates the financial impact of various enhancement scenarios; it does not offer a legal